Status:
UNKNOWN
Fibroblast Activation Protein Inhibitor PET/CT Imaging in Malignant Tumor of Digestive System
Lead Sponsor:
Zhongnan Hospital
Conditions:
Gastrointestinal Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
The purpose of this single center prospective study is to assess the value of FAPI PET imaging in predicting early postoperative recurrence of malignant tumor of digestive system and to evaluate the d...
Detailed Description
Malignant tumor of digestive system is one of the most common cancer types worldwide with high cancer-related mortalities. FDG PET/CT is an essential imaging modality in the tumor treatment and manage...
Eligibility Criteria
Inclusion
- Voluntarily participate and sign the informed consent.
- Patients with suspected or new diagnosed gastrointestinal cancer or other malignant tumor of digestive system.
- Complete clinical information, biochemical examination results, CT and/or MRI imaging examination, pathological information, and clinical/imaging follow-up data.
Exclusion
- Female patient who plan to become pregnant within 6 months, or pregnant or breast-feeding women.
- Allergic constitution.
- Those who are in poor general condition and cannot tolerate PET/CT examination.
- The researchers believe that he or she is not suitable to participate in this study.
Key Trial Info
Start Date :
June 23 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05420558
Start Date
June 23 2022
End Date
December 31 2023
Last Update
July 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China, 430071